Related Experiment Video
Updated: Mar 23, 2026

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis
Published on: August 16, 2021
Host-directed therapies for infectious diseases: current status, recent progress, and future prospects
Alimuddin Zumla1, Martin Rao2, Robert S Wallis3
1Centre for Clinical Microbiology, Division of Infection and Immunity, University College London (UCL), London, UK; National Institute for Health Research Biomedical Research Centre, UCL Hospitals NHS Foundation Trust, London, UK.
New host-directed therapies offer promising adjuncts to traditional treatments for infectious diseases, aiming to reduce mortality and disability. These strategies leverage insights into pathogen-host interactions and immune responses.
Area of Science:
- Infectious Diseases
- Immunology
- Pharmacology
Background:
- Infectious diseases remain a leading cause of death and disability globally, posing significant clinical challenges.
- Current antimicrobial treatments face limitations, necessitating novel therapeutic strategies.
- Emerging pathogens and ongoing epidemics of diseases like tuberculosis, HIV, and malaria underscore the need for improved interventions.
Purpose of the Study:
- To explore the potential of host-directed therapies (HDTs) as adjuncts to standard antimicrobial treatments.
- To highlight recent advancements in understanding pathogen-host interactions and immune responses for therapeutic development.
- To discuss clinically relevant examples of HDTs for various infectious diseases.
Main Methods:
- Review of recent scientific literature on pathogen-host interactions, pathogenesis, and immune responses.
- Identification and categorization of various host-directed therapeutic strategies.
- Discussion of clinically relevant examples and their mechanisms of action.
Main Results:
- Host-directed therapies are emerging as viable adjuncts to conventional antimicrobial treatments.
- HDTs encompass a range of approaches including repurposed drugs, immunomodulators, biologics, nutritional products, and cellular therapies.
- Progress has been made in identifying HDTs for bacterial, viral, and parasitic infections.
Conclusions:
- Host-directed therapies represent a promising new frontier in managing infectious diseases.
- These strategies offer a complementary approach to combatting high morbidity and mortality associated with infections.
- Further research and clinical application of HDTs are crucial for improving patient outcomes.
Related Concept Videos
Inhibitors of Viral Protein Synthesis
Microorganisms in Medicine and Therapeutics
Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Infection
The chain begins with pathogens: bacteria, viruses, fungi, prions, or parasites such as protozoa helminths. These can be present on the skin as transient or resident flora, or they can be acquired from the environment. Identifying and treating the type of infection and...
Transmission-based Precautions II: Airborne and Protective Environment
Airborne precautions:
Use airborne precautions when treating patients known or suspected to have diseases that spread through the air—for example, tuberculosis or measles. These organisms are present in smaller droplets expelled by an infected person and...
Sexually Transmitted Infections

